Data Add To Strengthening Efficacy Case For Takeda Dengue Vaccine
Executive Summary
Newly published details of interim clinical data for Takeda's candidate vaccine for dengue show activity across all serotypes that seems to bode well for an ongoing Phase III trial with the potential rival to the only currently available vaccine, Sanofi's Dengvaxia.
You may also be interested in...
Sanofi's Dengue Vaccine Health Warning Seen Hitting Product's Sales
The French drug manufacturer admits the world’s first dengue vaccine may be harmful when administered to individuals not previously infected with the disease.
Takeda's Dengue Vaccine Still Promising, But Could Be A Niche Market
Long-term Phase II data have backed Takeda's drive to study its dengue vaccine in Phase III, but to grow the market the company may have to reverse the reluctance of countries to fund public vaccination campaigns.
Biological E Taps Takeda Tech For Affordable Combo Vaccines
Takeda is to transfer selected vaccine technologies to an Indian manufacturer to enable the production of affordable combination vaccines for lower income countries, although likely volumes and prices remain unclear for now.